CoChat

Prevention and treatment of vivax malaria

Baird, J. Kevin, Schwartz, Eli, Hoffman, Stephen L. · 2007 · Current Infectious Disease Reports
Cited by 36

The DOI matches its Crossref record.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11908-007-0021-4

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 62

  1. Mendis K, Sina BJ, Marchesini P, Carter R: The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 2001, 64(1–2 Suppl):97–106. · DOI · Paper page
  2. Kochar DK, Saxena V, Singh N, et al.: Plasmodium vivax malaria. Emerg Infect Dis 2005, 11:132–134. · DOI · Paper page
  3. Krotoski WA, Collins WE, Bray RS, et al.: Demonstration of hypnozoites in sporozoite-transmitted Plasmodium vivax infection. Am J Trop Med Hyg 1982, 31:1291–1293. · DOI · Paper page
  4. Glynn JR, Bradley DJ: Inoculum size, incubation period and severity of malaria. Analysis of data from malaria therapy records. Parasitology 1995, 110(Pt 1):7–19. · doi:10.1017/s0031182000080999
  5. Church LW, Le TP, Bryan JP, et al.: Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis 1997, 175:915–920. · DOI
  6. Cogswell FB: The hypnozoite and relapse in primate malaria. Clin Microbiol Rev 1992, 5:26–35. · DOI · Paper page
  7. Schwartz E, Praise M, Kozarsky P, Cetron M: Delayed onset of malaria: in travelers: Implications for chemoprophylaxis. N Engl J Med 2003, 349:1510–1516. · DOI
  8. Hemmer CJ, Holst FG, Kern P, et al.: Stronger host response per parasitized erythrocyte in Plasmodium vivax or ovale than in Plasmodium falciparum malaria. Trop Med Int Health 2006, 11:817–823. · DOI
  9. Ravichandiran K, Sumitha K, Selvam RJ: Liver function tests in recurrent P. vivax malaria. Commun Dis 1996, 28:231–240.
  10. Lomar AV, Vidal JE, Lomar FP, et al.: Acute respiratory distress syndrome due to vivax malaria: case report and literature review. Braz J Infect Dis 2005, 9:425–430. · DOI
  11. Rodriguez-Morales AJ, Sanchez E, Vargas M, et al.: Anemia and thrombocytopenia in children with Plasmodium vivax malaria. J Trop Pediatr 2006, 52:49–51. · DOI
  12. Mohapatra MK, Padhiary KN, Mishra DP, Sethy G: Atypical manifestations of Plasmodium vivax malaria. Indian J Malariol 2002, 39:18–25.
  13. Beg MA, Khan R, Baig SM, et al.: Cerebral involvement in benign tertian malaria. Am J Trop Med Hyg 2002, 67:230–232. · DOI
  14. Mehta KS, Halankar AR, Makwana PD, et al.: Severe acute renal failure in malaria. J Postgrad Med 2001, 47:24–26.
  15. Gockel HR, Heidemann J, Lorenz D, Gockel I: Spontaneous splenic rupture in tertian malaria. Infection 2006, 34:43–45. · doi:10.1007/s15010-006-4126-8
  16. Oh MD, Shin H, Shin D, et al.: Clinical features of vivax malaria. Am J Trop Med Hyg 2001, 65:143–146. · DOI
  17. Baird JK: Resurgent malaria at the millennium: control strategies in crisis. Drugs 2000, 59:719–743. · DOI
  18. Baird JK: Resistance to chloroquine by Plasmodium vivax. Antimicrob Agents Chemother 2004, 48:4075–4083. · DOI · Paper page
  19. Ling J, Baird JK, Fryauff DJ, et al.: Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clin Infect Dis 2002, 35:825–833. · doi:10.1086/342578
  20. Soto J, Toledo J, Luzz M, et al.: Randomized, double-blind, placebo-controlled study of malarone for malaria prophylaxis in non-immune colombian soldiers. Am J Trop Med Hyg 2006, 75:430–433. · DOI
  21. Ohrt C, Richie TL, Widjaja H, et al.: Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997, 126:963–972. · DOI · Paper page
  22. Taylor WR, Richie TL, Fryauff DJ, et al.: Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis 1999, 28:74–81. · DOI
  23. Boudreau E, Schuster B, Sanchez J, et al.: Tolerability of prophylactic Lariam regimens. Trop Med Parasitol 1993, 44:257–265.
  24. Hill DR, Baird JK, Parise ME, et al.: Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006, 75:402–415. · DOI · Paper page
  25. Baird JK, Hoffman SL: Primaquine therapy for malaria. Clin Infect Dis 2004, 39:1336–1345. · DOI · Paper page
  26. Baird JK, Fryauff DJ, Basri H, et al.: Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. Am J Trop Med Hyg, 1995, 52:479–484. · doi:10.4269/ajtmh.1995.52.479
  27. Fryauff DJ, Baird JK, Basri H, et al.: Randomized, placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria in Indonesia. Lancet 1995, 346:1190–1193. · doi:10.1016/s0140-6736(95)92898-7
  28. Weiss WR, Oloo AJ, Johnson A, et al.: Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis 1995, 171:1569–1575. · doi:10.1093/infdis/171.6.1569
  29. Baird JK, Lacy MD, Basri H, et al.: Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis 2001, 33:1990–1997. · doi:10.1086/324085
  30. Soto J, Toledo J, Rodriquez M, et al.: Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998, 129:241–244. · doi:10.7326/0003-4819-129-3-199808010-00013
  31. Schwartz E, Regev-Yochay G: Primaquine as prophylaxis for malaria for non-immune travelers; comparison to mefloquine or doxycycline. Clin Infect Dis 1999, 29:1502–1506. · DOI
  32. Berman JD, Nielsen R, Chulay JD, et al.: Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model. Trans R Soc Trop Med Hyg 2001, 95:429–432. · doi:10.1016/s0035-9203(01)90206-8
  33. Arnold J, Alving AS, Hockwald RS, et al.: The effect of continuous and intermittent primaquine therapy on the relapse rate of Chesson strain vivax malaria. J Lab Clin Med 1954, 44:429–438.
  34. Arnold J, Alving AS, Hockwald RS, et al.: The antimalarial action of primaquine against the blood and tissue stages of falciparum malaria. J Lab Clin Med 1955, 46:391–397.
  35. Alving AS, Rucker K, Flanagan CL, et al.: Observations on primaquine in the prophylaxis and cure of vivax malaria. Proc. 6th International Congress of Tropical Medicine and Malaria 1959, 7:203–209.
  36. Powell RD, Brewer GJ: The effects of pyrimethamine, chloroquine and primaquine against exoerythrocytic forms of a strain of chloroquine-resistant Plasmodium falciparum from Thailand. Am J Trop Med Hyg 1967, 16:693–698. · DOI
  37. Centers for Disease Control and Prevention: Health Information for International Travel 2003–2004. Atlanta: US Department of Health and Human Services, Public Health Service; 2003.
  38. Baird JK, Fryauff DJ, Hoffman SL: Primaquine for prevention of malaria in travelers. Clin Infect Dis 2003, 37:1659–1667. · DOI
  39. Loeb RF, Clark WM, Coatney GR, et al.: Activity of a new antimalarial agent, chloroquine (SN 7618). JAMA 1946, 130:1069–1070. · doi:10.1001/jama.1946.02870160015006
  40. Baird JK, Wiady I, Sutanihardja A, et al.: Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia. Am J Trop Med Hyg 2002, 66:659–660. · DOI
  41. Pukrittayakamee S, Vanijononta S, Chantra A, et al.: Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J Infect Dis 1994, 169:932–935. · DOI
  42. Bray PG, Deed S, Fox E, et al.: Primaquine synergises the activity of chloroquine against chloroquine-resistant P. falciparum. Biochem Pharmacol 2005, 70:1158–1166. · doi:10.1016/j.bcp.2005.07.021
  43. Pukrittayakamee S, Imwong M, Looareesuwan S, White NJ: Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. Acta Trop 2004, 89:351–356. · doi:10.1016/j.actatropica.2003.10.012
  44. Maguire JD, Krisin, Marwoto H, et al.: Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia. Clin Infect Dis 2006, 42:1067–1072. · doi:10.1086/501357
  45. Lacy MD, Maguire JD, Barcus, et al.: Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. Clin Infect Dis 2002, 35:92–95. · doi:10.1086/343750
  46. Alving AS, Hankey DD, Coatney GR, et al.: Korean vivax malaria. II. Curative treatment with pamaquine and primaquine. Am J Trop Med Hyg 1953, 6:970–976. · doi:10.4269/ajtmh.1953.2.970
  47. Hankey DD, Jones Jr R, Coatney GR, et al.: Korean vivax malaria. I. Natural history and response to chloroquine. Am J Trop Med 1953, 2:958–969. · doi:10.4269/ajtmh.1953.2.958
  48. Coatney GR, Alving AS, Jones R Jr, et al.: Korean vivax malaria. V. Cure of the infection by primaquine administered during long-term latency. Am J Trop Med Hyg 1953, 6:985–988. · doi:10.4269/ajtmh.1953.2.985
  49. Wilairatana P, Silachamroon U, Krudsood S, et al.: Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax in Thailand. Am J Trop Med Hyg 1999, 61:973–977. · DOI
  50. Jelinek T, Nothdurft HD, Von Sonnenburg F, Loscher T: Long-term efficacy of primaquine in the treatment of vivax malaria in nonimmune travelers. Am J Trop Med Hyg 1995, 52:322–324. · doi:10.4269/ajtmh.1995.52.322
  51. Schwartz E, Regev-Yochay G, Kurnik D: Considering primaquine dose adjustment for radical cure of Plasmodium vivax malaria. Am J Trop Med Hyg 2000, 62:393–395. · doi:10.4269/ajtmh.2000.62.393
  52. Alving AS, Johnson CF, Tarlov AR, et al.: Mitigation of the hemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration. Bull World Health Organ 1960, 22:621–631.
  53. Alving AS, Arnold J, Hockwald RS, et al.: Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med 1955, 46:301–306.
  54. Hoffman SL: Malaria Vaccine Development: A Multi-Immune Response Approach. Washington DC: American Society for Microbiology; 1996.
  55. Miller LH, Hoffman SL: Research toward vaccines against malaria. Nat Med 1998, 4:520–524. · DOI
  56. Higgs ES, Sina B: Plasmodium vivax vaccine research: steps in the right direction. Am J Trop Med Hyg 2005, 73(5 Suppl):1–2. · DOI
  57. McCarthy VC, Clyde DF: Plasmodium vivax: correlation of circumsporozoite precipitation (CSP) reaction with sporozoite-induced protective immunity in man. Exp Parasitol 1977, 41:167–171. · doi:10.1016/0014-4894(77)90142-4
  58. Charoenvit Y, Collins WE, Jones TR, et al.: Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence. Science 1991, 251:668–671. · doi:10.1126/science.1704150
  59. Nardin EH, Nussenzweig V, Nussenzweig RS, et al.: Circumsprozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J Exp Med 1982, 156:20–30. · DOI · Paper page
  60. Collins WE, Nussenzweig RS, Ballou WR, et al.: Immunization of protein of Plasmodium vivax. Am J Trop Med Hyg 1989, 40:455–464. · doi:10.4269/ajtmh.1989.40.455
  61. Collins WE, Sullivan JS, Morris CL, et al.: Protective immunity induced in squirrel monkeys with a multiple antigen construct against the circumsporozoite protein of Plasmodium vivax. Am J Trop Med Hyg 1997, 56:200–210. · doi:10.4269/ajtmh.1997.56.200
  62. Collins WE, Jeffery GM, Roberts JM: A retrospective examination of reinfection of humans with Plasmodium vivax. Am J Trop Med Hyg 2004, 70:642–644. · DOI

Cited by

See all 36

Metadata

Authors
Baird, J. K., Schwartz, E., & Hoffman, S. L.
Venue
Current Infectious Disease Reports
Published
2007-01
Volume
9
Issue
1
Pages
39-46
ISSN
  • 1523-3847
  • 1534-3146
Cited by
36
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevention and treatment of vivax malaria. https://app.cochat.ai/papers/10.1007/s11908-007-0021-4
The paper
Baird, J. K., Schwartz, E., & Hoffman, S. L. (2007). Prevention and treatment of vivax malaria. Current Infectious Disease Reports. https://doi.org/10.1007/s11908-007-0021-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.